688065 凯赛生物
2026/06 - 中期
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额750,599404,123820,929569,451803,674
投资活动产生之现金流量净额(680,552)(725,883)(823,061)(1,558,810)(4,198,216)
筹资活动产生之现金流量净额194,8564,315,189149,492(262,160)403,878
汇率变动对现金及现金等价物的影响(117,899)(58,920)24,82540,22159,983
现金及现金等价物净增加/(减少)147,0043,934,510172,185(1,211,298)(2,930,681)
期初现金及现金等价物余额9,120,4755,185,9655,013,7806,225,0779,155,758
期末现金及现金等价物余额9,267,4799,120,4755,185,9655,013,7806,225,077